Global pharmaceutical and biotech companies are opening their wallets to secure Chinese-developed new drug candidates. As ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

The "The Pharma Mini MBA (July 8th - July 10th, 2026)" has been added to ResearchAndMarkets.com's offering. The Pharma Mini MBA is a unique, three-day virtual management program tailor-made for ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

We'll know more about the company's medium-term prospects by the end of the year.

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.7% in the afternoon session after Jefferies ...

In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected ...

In this week’s edition of InnovationRx, we look at the first robotic cataract surgeries in humans, the underbelly of ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...